Media coverage about NantKwest (NASDAQ:NK) has trended somewhat negative recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NantKwest earned a media sentiment score of -0.14 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 43.464226070074 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern’s rankings:

A number of analysts have commented on NK shares. Zacks Investment Research raised NantKwest from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a report on Friday, January 12th. BidaskClub lowered NantKwest from a “sell” rating to a “strong sell” rating in a report on Friday, January 19th. Three investment analysts have rated the stock with a sell rating and three have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $4.00.

Shares of NK opened at $4.11 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.35 and a quick ratio of 6.35. NantKwest has a one year low of $2.71 and a one year high of $8.45. The firm has a market capitalization of $318.73, a P/E ratio of -3.43 and a beta of 2.84.

NantKwest Company Profile

NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Insider Buying and Selling by Quarter for NantKwest (NASDAQ:NK)

Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.